aTyr Pharma (ATYR): After interim data for an ongoing study, two experts see potential for a price multiplication!
Reading Time: 3 minutes
aTyr Pharma (ATYR) presented positive results from an interim analysis of the ongoing Phase 2 study EFZO‑CONNECT™ on June 4, in which the drug Efzofitimod is being investigated for systemic sclerosis with lung involvement (SSc‑ILD). All eight patients showed stabilized or improved skin scores, as measured by the modified Rodnan Skin Score (mRSS). Particularly encouraging was that three out of four patients with the diffuse form of the disease reported a clinically relevant decrease in skin fibrosis of at least four points within 12 weeks....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
